Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

BGR vs BME: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

BGR Captures Overall Composite Edge (62.3 BUY vs 46.3 HOLD), While BME Leads 1–0 on Growth & Valuation Pillars

BGR Overall Winner 6-Pillar Tally: BGR 0 – 1 BME (5 Tie) Matrix Metrics: BGR 1 – 3 BME

As of Nov 16, 2026, Blackrock Energy and Resources Trust (BGR) captures the overall head-to-head institutional edge over Blackrock Health Sciences Trust (BME) on higher Unified Composite conviction (62.3/100 BUY vs. 46.3/100 HOLD) after splitting the core matrix 1–3 (led by composite factor balance), while BME wins 1–0 across the 6-pillar growth and valuation breakdown. BGR trades at $16.93 (N/M Forward P/E, N/A operating margin) versus BME at $47.08 (N/M Forward P/E, N/A operating margin).

  • Growth vs. Quality Trade-Off: BGR earns the overall head-to-head edge with a stronger Unified Composite Score (62.3/100 BUY vs. BME 46.3/100 HOLD) and -0.35β · 28% Vol risk profile, whereas BME leads top-line expansion (N/A YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About BGR vs BME
BGR NYSE Head-to-Head Winner
Blackrock Energy and Resources Trust
Institutional Equity
$16.93
-1.91% 1D
Market Cap $345.7M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol -0.35β · 28% Vol
Unified Composite Score
62.3 / 100 BUY
Tech 60.0 Fund 53.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 40
RSI-14: 39.7 · SMA20: $17.76 · SMA50: $17.60
BME NYSE
Blackrock Health Sciences Trust
Institutional Equity
$47.08
-1.07% 1D
Market Cap $487.9M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.42β · 19% Vol
Unified Composite Score
46.3 / 100 HOLD
Tech 36.0 Fund 36.0 Flow 50.0 Mom 31.6
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (1.1% over 20 days), RSI 60
RSI-14: 59.7 · SMA20: $46.65 · SMA50: $45.16

6-Pillar Scorecard Institutional Category Breakdown (BGR 0 – 1 BME)

Columns: Metric · BGR · BME
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale BME
Revenue Growth (YoY) N/A N/A
Earnings Growth (YoY) N/A N/A
TTM Revenue (USD) N/A N/A
Market Cap $345.7M $487.9M
3. Profitability & Quality Tie
Gross Margin N/A N/A
Operating Margin N/A N/A
Net Profit Margin N/A N/A
Return on Equity (ROE) N/A N/A
4. Balance Sheet & Cash Flow Tie
Cash Generation (TTM) N/A N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage N/A ROE N/A ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Institutional Equity Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: BGR (1) vs BME (3)
Institutional Metric BGR BME Criterion Row Edge
Market Capitalization
Scale
$345.7M $487.9M Larger Scale BME
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
N/A N/A Higher Growth Tie
Operating Margin (TTM)
Profitability
N/A N/A Higher Margin Tie
Net Profit Margin
Profitability
N/A N/A Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
N/A N/A Higher ROE Tie
52-Week Range Position
Momentum
63% ($13–$19) 89% ($38–$48) Stronger Trend BME
Beta / 30D Volatility
Risk Regime
-0.35β · 28% Vol 0.42β · 19% Vol Lower Realized Risk BME
Unified Institutional Score
Composite Signal
62.3 / 100 (BUY) 46.3 / 100 (HOLD) Higher Composite BGR
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) N/A (N/A ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon BME +14.77 pp
BGR: -7.79% · BME: +6.98%
3M Horizon BME +6.63 pp
BGR: -1.68% · BME: +4.95%
6M Horizon BME +20.55 pp
BGR: +1.32% · BME: +21.87%
1Y Horizon BGR +5.88 pp
BGR: +22.59% · BME: +16.71%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BGR vs BME. Trailing 12-month operating profitability (BGR N/A vs BME N/A) and valuation multiples (BGR N/M vs BME N/M Forward P/E) are benchmarked directly in Pillar 4 below.

BGR ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
BME ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
BGR UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BGR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
BME UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BME Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
BGR Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with $345.7M market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
BME Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with $487.9M market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ BGR vs BME Key Questions & Quantitative Answers

As of Nov 16, 2026, Blackrock Energy and Resources Trust (BGR) captures the overall head-to-head institutional edge over Blackrock Health Sciences Trust (BME) on higher Unified Composite conviction (62.3/100 BUY vs. 46.3/100 HOLD) after splitting the core matrix 1–3 (led by composite factor balance), while BME wins 1–0 across the 6-pillar growth and valuation breakdown. BGR trades at $16.93 (N/M Forward P/E, N/A operating margin) versus BME at $47.08 (N/M Forward P/E, N/A operating margin). Growth vs. Quality Trade-Off: BGR earns the overall head-to-head edge with a stronger Unified Composite Score (62.3/100 BUY vs. BME 46.3/100 HOLD) and -0.35β · 28% Vol risk profile, whereas BME leads top-line expansion (N/A YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.

BME leads the Growth & Scale pillar: BGR posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with BME at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, BGR generates N/A in USD-normalized revenue versus N/A for BME. In operating R&D and SG&A reinvestment, BGR deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for BME.

BGR and BME trade at balanced relative valuation multiples. BGR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas BME trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BGR (N/A ROE) versus BME (N/A ROE) capital efficiency.

In options market volatility and institutional positioning, BGR carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.35β · 28% Vol realized risk). By comparison, BME carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.42β · 19% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.